



MONIKA HEGI, PhD

Prof. Monika E Hegi has a PhD in natural sciences from the Federal Institute of Technology in Zurich (ETHZ), and pursued post-doctoral training in molecular toxicology and molecular carcinogenesis at the National Institute of Environmental Health Sciences (NIEHS), NIH, RTP, NC, USA.

In 1993 she started her research on brain tumors at the Institute of Neuropathology in Zurich. Since 1998 she directs the laboratory of Brain Tumor Biology and Genetics in the Department of Clinical Neurosciences at the University Hospital Lausanne. Combining multidimensional molecular analyses of tumors and experimental approaches, her research aims at identifying new molecular targets and predictive factors for response to therapy and outcome in brain tumor patients, with a special interest in cancer epigenomics.

These efforts are in close collaboration with local, and international cooperative groups, in particular the Brain Tumor Group at the EORTC, where she contributes to translational research in clinical trials and is involved in the SPECTA (biomarker) project. This fruitful collaboration paved the way to the implementation of the *MGMT* methylation status as the first predictive biomarker in glioblastoma that led to a paradigm change in the field.